GlobalRPh RX List - OLPRUVA
- Product / population
- Sodium phenylbutyrate - OLPRUVA oral suspension; selected source sections only, not a complete prescribing monograph.
- Renal measure
- Qualitative renal statement; no numerical renal algorithm inferred.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
Renal impairment has not been studied. Monitor plasma ammonia closely when initiating OLPRUVA in patients with impaired renal function. Urinary excretion of phenylacetylglutamine may cause potassium loss; monitor serum potassium. The selected renal passages do not supply a numerical reduction or dialysis regimen. This sodium phenylbutyrate product is not glycerol phenylbutyrate; do not transfer the other product's volume or dosing schedule.